{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:47:38Z","timestamp":1786646858233,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.msard.2018.07.024","type":"journal-article","created":{"date-parts":[[2018,7,20]],"date-time":"2018-07-20T14:26:00Z","timestamp":1532096760000},"page":"46-49","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Gynecological adverse effects of natalizumab administration: Case report and review of the literature"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8945-4874","authenticated-orcid":false,"given":"Georgios-Marios","family":"Makris","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonida","family":"Mene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandros","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileia","family":"Xyla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco-Johannes","family":"Battista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-5528","authenticated-orcid":false,"given":"Theodoros N.","family":"Sergentanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2018.07.024_bib0001","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1136\/jnnp-2013-306936","article-title":"Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results","volume":"85","author":"Butzkueven","year":"2014","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2018.07.024_bib0003","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1007\/s00415-012-6414-9","article-title":"Natalizumab treatment of multiple sclerosis in Spain: results of an extensive observational study","volume":"259","author":"Fernandez","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2018.07.024_bib0004","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ncpuro1298","article-title":"Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management","volume":"6","author":"Fletcher","year":"2009","journal-title":"Nat. Clin. Pract. Urol."},{"key":"10.1016\/j.msard.2018.07.024_bib0007","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/01.wnl.0000343880.13764.69","article-title":"GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study","volume":"72","author":"Goodman","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.024_bib0008","doi-asserted-by":"crossref","unstructured":"Gupta, V., Nag, D., Garg, P. 2017. Recurrent urinary tract infections in women: How promising is the use of probiotics? Indian J. Med. Microbiol. 35, 347\u2013354.","DOI":"10.4103\/ijmm.IJMM_16_292"},{"key":"10.1016\/j.msard.2018.07.024_bib0010","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/1352458510394701","article-title":"A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis","volume":"17","author":"Holmen","year":"2011","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2018.07.024_bib0011","first-page":"321","article-title":"An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis","volume":"52","author":"Horga","year":"2011","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2018.07.024_bib0013","article-title":"Cognitive evolution in natalizumab-treated multiple sclerosis patients","volume":"2","author":"Jacques","year":"2016","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2018.07.024_bib0014","doi-asserted-by":"crossref","first-page":"e210","DOI":"10.1212\/NXI.0000000000000210","article-title":"Disrupted balance of T cells under natalizumab treatment in multiple sclerosis","volume":"3","author":"Kimura","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"Suppl 3","key":"10.1016\/j.msard.2018.07.024_bib0015","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10072-010-0356-8","article-title":"Three years of experience: the Italian registry and safety data update","volume":"31","author":"Mancardi","year":"2011","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2018.07.024_bib0016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1212\/WNL.0000000000000541","article-title":"Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study","volume":"83","author":"O'Connor","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2018.07.024_bib0017","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1331.2008.02517.x","article-title":"Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study","volume":"16","author":"Oturai","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2018.07.024_bib0018","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00415-009-5294-0","article-title":"Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice","volume":"257","author":"Outteryck","year":"2010","journal-title":"J. Neurol."},{"issue":"Suppl 3","key":"10.1016\/j.msard.2018.07.024_bib0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10072-010-0345-y","article-title":"Swedish natalizumab (Tysabri) multiple sclerosis surveillance study","volume":"31","author":"Piehl","year":"2011","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.msard.2018.07.024_bib0020","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.msard.2018.07.024_bib0021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168376","article-title":"Natalizumab-related progressive multifocal leukoencephalopathy in multiple sclerosis: findings from an Italian independent registry","volume":"11","author":"Prosperini","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2018.07.024_bib0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1468-1331.2009.02728.x","article-title":"Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries","volume":"17","author":"Putzki","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2018.07.024_bib0024","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1586\/14737175.4.4.571","article-title":"Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS","volume":"4","author":"Rudick","year":"2004","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.msard.2018.07.024_bib0025","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2018.07.024_bib0027","doi-asserted-by":"crossref","first-page":"e292","DOI":"10.1212\/NXI.0000000000000292","article-title":"Natalizumab treatment leads to an increase in circulating CXCR3-expressing B cells","volume":"3","author":"Saraste","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2018.07.024_bib0028","doi-asserted-by":"crossref","first-page":"399","DOI":"10.33588\/rn.5909.2013479","article-title":"The efficacy and safety of natalizumab for the treatment of multiple sclerosis in Portugal: a retrospective study","volume":"59","author":"Sousa","year":"2014","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.msard.2018.07.024_bib0029","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13760-014-0308-9","article-title":"Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program","volume":"114","author":"van Pesch","year":"2014","journal-title":"Acta Neurol. Belg."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818302323?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034818302323?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:45:02Z","timestamp":1761900302000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034818302323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":22,"alternative-id":["S2211034818302323"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2018.07.024","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gynecological adverse effects of natalizumab administration: Case report and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2018.07.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}